|
Two drugs combined with insulin are better than one in regulating
the blood-sugar levels of type 2 diabetics without the common
side effect of weight gain, according to a study reported
in the July issue of Diabetes Care.
Type 2
diabetics being treated with drugs typically take insulin
and only one of the drugs. Such patients often lower their
blood sugar below the 7 percent limit suggested by the American
Diabetes Association, but they also tend to gain weight and
to increase their insulin doses.
University
of Texas Southwestern Medical Center researchers say they
are the first to analyze the safety and effectiveness of triple
therapy using insulin, metformin and a drug in the thiazolidinedione
family.
"We've
shown spectacular control of blood sugar levels in the absence
of weight gain, a common side effect of drug therapies for
type 2 diabetes," said study author Dr. Philip Raskin,
a UT Southwestern professor of internal medicine. "And
we can keep the blood sugar under control with relative ease.
This is a step in the right direction for effectively treating
type 2 diabetes."
In the
UT Southwestern study, all 28 patients who used triple therapy
reduced their blood-sugar levels below 7 percent without increasing
insulin. Patients who took the therapy in a particular order,
with the thiazolidinedione administered after a period of
insulin and metformin use, actually showed a slight decrease
in weight, along with lowering blood sugar.
Almost
60 percent of all patients, regardless of what order the drugs
were taken, reduced blood sugar levels below 6 percent.
Keeping
blood-sugar levels under 6 percent or 7 percent significantly
reduces the risk of eye disease, kidney disease and amputations,
said lead researcher Suzanne Strowig, a UT Southwestern faculty
member.
Drugs
like metformin and those in the thiazolidinedione family help
the body regulate the amount of glucose in the blood and decrease
the amount of glucose made by the liver. They also help the
body more effectively use its own insulin, according to the
researchers.
"With
many of these drugs, though, people have been unable to control
their weight," Raskin said. "But put together, especially
in a particular order, they show the most promise."
Source:
Diabetes Week staff,
July 19, 2004

|